Therefore, this finding indicated that SIK2 activators or p300 inhibitors, by decreasing acetylation of p300, may offer novel therapeutic measures to treat hepatic diseases such as liver fibrosis (Figure 3(a)). The gene discussed is EP300; the disease is Hepatic fibrosis.